MedPath

Effect of Discontinuation of Sugar Sweetened Beverages

Not Applicable
Completed
Conditions
Type 2 Diabetes
Obesity
Interventions
Behavioral: discontinuation of sugar sweetened beverages
Registration Number
NCT00585897
Lead Sponsor
Duke University
Brief Summary

Purpose The purpose of this study is to investigate the effects of discontinuation of sugar sweetened beverages on hemoglobin A1c (HbA1c) and plasma fasting and post-prandial blood glucose in a population with type 2 diabetes.

Hypothesis Elimination of sugar sweetened beverages from the diet for a 4 week period will lead to a decrease in HbA1c and plasma fasting and 2 hour post prandial blood glucose in a population with a history of type 2 diabetes and high consumption of sugar sweetened beverages.

Specific aims to test hypothesis

1. Investigate how elimination of sugar sweetened beverages from the diet affects HbA1c and plasma fasting and two hour post prandial blood glucose.

2. Test the feasibility of carrying out a simple diet intervention in an outpatient population with type 2 diabetes.

Detailed Description

Type and Design of Study This will be a pilot study including adult patients age \>/= 18 diagnosed with Type 2 Diabetes who are patients at the Duke Outpatient Clinic (DOC) or patients in the general medicine or family practice clinics in Durham County. The intervention will be elimination of sugar sweetened beverages from the diet in a population of type 2 diabetic subjects for four weeks. Sugar sweetened beverages will be defined as any liquid beverage containing calories that can be attributed to natural or added sugar. This will not include beverages that contain mainly artificial sweeteners (e.g.: NutraSweet®, saccharin, Splenda®, or Equal®), plain milk, or water.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
5
Inclusion Criteria
  1. Prior diagnosis of Type 2 Diabetes for at least 1 year based on one of the following:

    • Fasting blood glucose >126 on two separate occasions
    • Random blood glucose >200 with symptoms
    • Abnormal 75 or 100 gram Oral Glucose Tolerance Test (OGTT) defined as: fasting blood glucose >100, 2hour post prandial blood sugar of >140
    • On medications for diabetes (oral or insulin)
  2. Age >/=18

  3. Stable but uncontrolled blood glucose (Hemoglobin A1C >7%, </= 12%)

  4. Ingestion of at least three eight ounce servings of sugar sweetened beverage daily.

  5. Stable solid diet and exercise pattern and agreement not to change these during the study

  6. Able and willing to maintain a complete diet diary for three days each week of the study (total of 12 days of recording)

  7. Able to attend regular study visits

  8. Able to give informed consent

  9. Working phone number in order to contact patient

  10. Able and willing to understand and comply with the intervention

Exclusion Criteria
  1. Women who are known to be pregnant at enrollment based on a positive pregnancy test. Pregnancy test will be given to all female subjects of child bearing age prior to enrollment in the study. Pregnant women will be excluded on the basis that blood glucose data are significantly affected by the physiology of pregnancy. This exclusion is not based on any potential risk to the pregnant women or fetus.
  2. Individuals <18 years of age
  3. Diagnosis of Type 1 Diabetes
  4. Malabsorbtive syndrome of any type (will be determined based on medical history from patient and/or medical chart)
  5. On Acarbose prior to start of study
  6. On a weight loss diet within one month of enrollment

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Behavioral counselingdiscontinuation of sugar sweetened beveragesIndividual sessions which utilize motivational interviewing to assist participants to discontinue sugar sweetened beverages from their diet.
Primary Outcome Measures
NameTimeMethod
Hemoglobin A1c4 weeks for each participant
Secondary Outcome Measures
NameTimeMethod
Fasting glucose4 weeks

Trial Locations

Locations (1)

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath